These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21788224)

  • 21. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
    Kaufman D; Boyle R; Hazen KC; Patrie JT; Robinson M; Donowitz LG
    N Engl J Med; 2001 Dec; 345(23):1660-6. PubMed ID: 11759644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
    Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
    Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study.
    Elwatidy S; Jamjoom Z; Elgamal E; Zakaria A; Turkistani A; El-Dawlatly A
    Spine (Phila Pa 1976); 2008 Nov; 33(24):2577-80. PubMed ID: 19011538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.
    Bloom B; Schelonka R; Kueser T; Walker W; Jung E; Kaufman D; Kesler K; Roberson D; Patti J; Hetherington S;
    Pediatr Infect Dis J; 2005 Oct; 24(10):858-66. PubMed ID: 16220082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature.
    Weisman LE
    Arch Pediatr; 2007 Sep; 14 Suppl 1():S31-4. PubMed ID: 17939955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
    Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous gammaglobulin in the prophylaxis of late sepsis in very-low-birth-weight infants: preliminary results of a randomized, double-blind, placebo-controlled trial.
    Bussel JB
    Rev Infect Dis; 1990; 12 Suppl 4():S457-61; discussion S461-2. PubMed ID: 2194270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study.
    Clapp DW; Kliegman RM; Baley JE; Shenker N; Kyllonen K; Fanaroff AA; Berger M
    J Pediatr; 1989 Dec; 115(6):973-8. PubMed ID: 2585237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection.
    Bloom BT
    Expert Opin Investig Drugs; 2006 Jun; 15(6):703-7. PubMed ID: 16732720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staphylococcus aureus bacteremia.
    Gurevich I
    Am J Infect Control; 1987 Oct; 15(5):226-7. PubMed ID: 3674541
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.
    Daifuku R; Haenftling K; Young J; Groves ES; Turrell C; Meyers FJ
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2349-51. PubMed ID: 1444318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Anyone Safe From Sepsis?
    Pannu SR; Crouser ED
    Chest; 2022 Jul; 162(1):14-16. PubMed ID: 35809924
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants.
    Patel M; Kaufman DA
    Expert Opin Biol Ther; 2015 Apr; 15(4):595-600. PubMed ID: 25736524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial reprogramming of PBMCs impairs monocyte phagocytosis and modulates adaptive T cell responses.
    André MC; Gille C; Glemser P; Woiterski J; Hsu HY; Spring B; Keppeler H; Kramer BW; Handgretinger R; Poets CF; Lauber K; Orlikowsky TW
    J Leukoc Biol; 2012 Jun; 91(6):977-89. PubMed ID: 22427683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.